Abstract
BACKGROUND: Spinal muscular atrophy is a progressive neurodegenerative disorder that can be treated with intrathecal antisense oligonucleotide therapy (nusinersen). However, administration is often complicated by posterior spinal fusion and neuromuscular scoliosis, necessitating a transforaminal approach. PURPOSE: To assess the safety profile of the transforaminal approach for intrathecal access. DATA SOURCES: Searches of the PubMed, Web of Science, and SCOPUS databases. STUDY SELECTION: Thirteen articles were selected based on inclusion of transforaminal access and appropriate clinical information about the procedure. DATA ANALYSIS: Complications were taken from the included articles and aggregated based on Cardiovascular and Interventional Radiological Society of Europe scale adverse event grading. DATA SYNTHESIS: Total number of complications and grade of complications were analyzed, by year and in total. LIMITATIONS: Selection bias in publication, small patient population size, and variability of the procedure limits the available data. CONCLUSIONS: Transforaminal approach is a safe alternative for intrathecal access in patients with spinal muscular atrophy and may be applicable to a larger patient population.